New Sermo Event Report assesses physicians' perception of multiple sclerosis drugs

Sermo (http://www.sermo.com), the world's largest online physician's community, today announced a new Sermo Event(TM) Report assessing physician perception of FDA's "refuse to file" (RTF) letter on EMD Serono's Cladribine tablets and its potential impact, if any, on Novartis' oral MS agent in development; Fingolimod. Cladribine is expected to be one of the first oral agents to be approved for the treatment of relapsing and remitting multiple sclerosis.

According to the findings, most Neurologists are anxious for an oral MS agent and believe Cladribine will ultimately be approved. Physicians also indicate that patients are eagerly awaiting an oral agent even if it comes with higher side effects. However, the majority of Neurologists express the need for more long-term safety data and are apprehensive to increase adoption after deaths from PML associated with Tysabri.

Highlights of key findings include:

  • The opportunity for oral MS drugs remains significant. Patients are aware of both new agents and are asking about their progress.
  • Success at promoting early adoption of both drugs will likely be driven by educating physicians around safety profiles.
  • Neurologists are closely following the clinical trials and appear to distinguish between Fingolimod and Cladribine.

The report covers a variety of areas, including:

  • Anticipated physician prescribing and usage patterns.
  • Physician perception of the RTF letter on Cladribine and the impact, if any, on Fingolimod.
  • Necessary safety-data required by physicians before adopting Cladribine.
  • How physicians would use both drugs for relapsing and remitting MS.
  • Percentage of relapsing-remitting MS patients that would choose an oral administration over injectable.

About Sermo Event Reports and Physician Respondents

Sermo Event Reports rapidly assess physician reaction to major events impacting the US pharmaceutical market. The new report titled "Cladribine/Fingolimod: Estimating the Impact of Oral MS Agents" polled 300 US Neurologists. All respondents are verified and credentialed, ensuring they have valid, active licenses to practice medicine in the United States. Reports are available for purchase at http://www.sermo.com/cladribine or by calling 877-778-3963.

Source:

Comments

  1. Eric Eric United States says:

    With recent research the perception that MS is an Auto Immune disease is incorrect, it is a vascular disease.  It can be concluded that the cause of MS is the weakening of blood vessels in the brain due to the vascular issue of Chronic Cerebrospinal Venous Insufficiency and is NOT an auto immune disease.   The underlying vascular cause is what gives MS it’s “progressive” nature.  When the vessels have weaken as shown in the German Study iron is able to make it’s way into the brain causing an inflammatory response by the immune system.  With surgery the progression of MS can be stopped.    

    • Kelly Kelly United States says:

      At this point I would try that and believe it.  I have been sick, not working for 4 plus years.  Have tried almost every treatment out there and nothing has shown any improvement.  Just got out of the hospital right before Thanksgiving.  I could not breath.  After many tests, I nhave now nbeen diagnosed with Asthma...never a breathing problem in my life.  And, after an endocospy my food is barely digesting, it is taking days.  My body is just starting down.  I am just holding on to my first grandchild to be born in 1 - 2 weeks.  May God grant me that time.  

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Intermittent fasting outperforms traditional drugs in managing early type 2 diabetes